VER 155008: Adenosine-Derived HSP 70 Inhibitor for Cancer and Phase Separation Research

Executive Summary: VER 155008 is a potent, selective adenosine-derived small molecule inhibitor targeting the Hsp70 family of molecular chaperones, with an IC₅₀ of 0.5 μM for Hsp70 ATPase activity inhibition (Agnihotri et al., 2025, DOI). Its application disrupts Hsp70-mediated anti-apoptotic functions, resulting in apoptosis and cell growth inhibition in multiple human cancer cell lines. The compound’s effects extend to modulating liquid-liquid phase separation (LLPS) dynamics, especially in models of proteinopathy and cancer. VER 155008 is soluble at ≥27.8 mg/mL in DMSO and is supplied as a solid for research use, requiring storage at -20°C. It is widely used in apoptosis assays, studies of chaperone pathways, and cancer biology workflows (ApexBio).

Biological Rationale

Heat shock proteins (HSPs) are essential molecular chaperones, with Hsp70 (including Hsc70 and Grp78) playing a pivotal role in protein folding, protection from stress-induced damage, and regulation of apoptosis. Overexpression of Hsp70 is documented in several cancers, where it confers survival advantages and resistance to therapy. In neurodegenerative diseases, Hsp70 modulates liquid-liquid phase separation (LLPS) and the dynamics of protein condensates, such as TDP-43, impacting proteinopathy (Agnihotri et al., 2025, DOI). Targeting Hsp70’s ATPase activity disrupts its chaperone function, sensitizing cancer cells to apoptosis and altering LLPS behavior in disease-relevant models. VER 155008 is designed to probe these mechanisms by providing selective, ATPase-pocket–specific inhibition (VER 155008 product page).

Mechanism of Action of VER 155008 (HSP 70 inhibitor, adenosine-derived)

VER 155008 binds competitively to the ATPase domain of Hsp70 family proteins, with an IC₅₀ of 0.5 μM for Hsp70, blocking ATP hydrolysis required for chaperone cycling (Agnihotri et al., 2025). This inhibition interrupts the conformational changes necessary for substrate binding and release, thereby impairing protein refolding and stress response. In cancer cells, this leads to destabilization of anti-apoptotic client proteins, increased apoptosis rates, and reduced cell proliferation. VER 155008 also indirectly promotes degradation of Hsp90 client proteins by interfering with the chaperone network. In models of proteinopathy, inhibiting Hsp70 alters the phase separation properties of proteins like TDP-43, as shown in ALS-related studies (Agnihotri et al., 2025, DOI).

Evidence & Benchmarks

• VER 155008 inhibits Hsp70 ATPase activity with an IC₅₀ of 0.5 μM at 25°C in biochemical assays (Agnihotri et al., 2025, DOI).
• It induces apoptosis and proliferation inhibition in human breast (BT474, MB-468) and colon (HCT116, HT29) cancer cell lines, with GI₅₀ values ranging from 5.3 μM to 14.4 μM after 72 h exposure (ApexBio).
• VER 155008 modulates liquid-liquid phase separation and TDP-43 nuclear condensate fluidity under poly-PR stress in ALS models (Agnihotri et al., 2025, DOI).
• It is soluble in DMSO at ≥27.8 mg/mL, insoluble in water, and moderately soluble in ethanol with warming and sonication (ApexBio).
• VER 155008 promotes degradation of Hsp90 client proteins via chaperone network disruption (Agnihotri et al., 2025, DOI).

Applications, Limits & Misconceptions

VER 155008 is primarily used in biochemical and cellular assays to:

• Elucidate Hsp70 chaperone pathway function in cancer and neurodegeneration models.
• Probe mechanisms of apoptosis via inhibition of Hsp70’s anti-apoptotic activity.
• Study phase separation and condensate dynamics, especially in TDP-43 and related proteinopathies (VER 155008: Precision HSP 70 Inhibition in Cancer and Phase Separation — this article expands on the translational impact and provides deeper evidence for LLPS modulation).
• Serve as a reference tool compound for benchmarking new Hsp70-targeting chemical probes (Strategic Hsp70 Inhibition with VER 155008 — this article focuses on strategic use, whereas the present article supplies updated mechanistic and evidence-based insights).

Recent research highlights that Hsp70 activity can modulate the fluidity and aggregation state of TDP-43 nuclear condensates; inhibition by VER 155008 may thus impact both cancer and neurodegenerative disease models (Agnihotri et al., 2025, DOI). For a detailed exploration of the mechanistic underpinnings of ATPase inhibition, see VER 155008: Dissecting Hsp70 ATPase Inhibition in Cancer, which this article updates with the latest TDP-43 phase separation evidence.

Common Pitfalls or Misconceptions

• VER 155008 is not selective for Grp78; its primary targets are Hsp70 and Hsc70, with lower potency against Grp78.
• The compound is not suitable for in vivo therapeutic use due to limited pharmacokinetic data and off-target effects; it is intended for research applications only.
• Long-term storage of VER 155008 solutions is not recommended; solutions should be prepared fresh and used promptly.
• VER 155008 is not soluble in water; use DMSO or ethanol (with gentle warming) for dissolution.
• Hsp70 inhibition may have cell-type or context-specific effects; results must be interpreted in the appropriate biological framework.

Workflow Integration & Parameters

VER 155008 is supplied as a solid (SKU: A4387) and should be stored at -20°C in a desiccated environment. For cellular assays, dissolve at ≥27.8 mg/mL in DMSO; for moderate solubility in ethanol, apply gentle warming and ultrasonic treatment. Typical working concentrations range from 0.5 μM (for enzymatic ATPase assays) to 15 μM (for cellular apoptosis or proliferation assays). Avoid repeated freeze-thaw cycles and long-term storage of stock solutions. The A4387 kit includes technical documentation for handling and storage. Integration into apoptosis assays or phase separation studies should follow published benchmarks and internal controls.

Conclusion & Outlook

VER 155008 remains a critical tool for dissecting the Hsp70 chaperone pathway, apoptosis, and LLPS in cancer and neurodegenerative research. Its high potency, defined mechanism, and published benchmarks enable reproducible, mechanistically interpretable results. Future directions include the development of next-generation analogs with improved selectivity and pharmacokinetics, as well as expanded use in high-content phase separation and proteinopathy screening assays (Agnihotri et al., 2025).